HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
INSIDE INDUSTRY
Joslin Diabetes Center Forms Alliance with Johnson & Johnson Innovation to Identify Exercise-Related Drug Targets to Improve Diabetes Management
Joslin Diabetes Center announces a research and development alliance with Johnson & Johnson Innovation and its affiliate Janssen Research & Development, LLC, to identify and advance early-stage, novel therapeutic projects for potential for commercialization and product development. The first joint project selected in the alliance will focus on identifying exercise-related drug targets for developing new diabetes treatments.

“Joslin is uniquely positioned to translate findings in the laboratory into new approaches for treatment of diabetes, and our alliance with Johnson & Johnson Innovation and Janssen Research & Development is an excellent example of how we can move our early discoveries to the clinic with our complementary capabilities,” said Dr. Nandan Padukone, Ph.D., MBA, VP of Commercialization and Ventures at Joslin. “We will continue to explore other technologies with Johnson & Johnson Innovation and mechanisms such as venture creation to advance them quickly towards drug development.”

The new alliance is based on pioneering studies by Joslin researchers showing that exercise can train multiple tissues in the body that in turn stimulate metabolic improvements in other tissues. “The concept of tissue-to-tissue communication has been around for a while, but more recently we have realized that ‘trained’ tissues may communicate to beneficially affect other tissues,” said Laurie Goodyear, Ph.D., Co-Head of the Integrative Physiology and Metabolism Section at Joslin and senior investigator on this research presented earlier this year at the American Diabetes Association's 73rd annual Scientific Sessions. “Our efforts now are to derive specific factors that help this effect and explore the development into potential therapies for diabetes.”

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy